BioVentrix

What BioVentrix does

BioVentrix is a privately held, clinical-stage medical device company founded in 2003 that develops minimally invasive therapies for congestive heart failure. The company's lead product, the Revivent System (also known as the Revivent TC System), is a hybrid transcatheter ventricular restoration platform that uses pairs of titanium micro-anchors connected by PEEK tethers to reshape the dilated left ventricle and exclude scarred, non-functioning myocardium in patients with ischemic heart failure and reduced ejection fraction. The Less Invasive Ventricular Enhancement (LIVE) procedure is performed by a Heart Team—a cardiothoracic surgeon placing external anchors through a small chest incision and an interventional cardiologist delivering internal anchors via a catheter through the right ventricle—on a beating heart without cardiopulmonary bypass, and is integrated with Philips Healthcare's HeartNavigator 3.0 image fusion software for intra-operative navigation.

BioVentrix generates revenue through direct hospital sales of its Revivent System hardware, currently commercialized in Europe following CE Mark certification in June 2016 and extended in January 2020. The company has built direct sales infrastructure including a VP of Sales for Europe and VP of U.S. Sales, with active commercialization geographies spanning Germany (via the BioVentrix GmbH subsidiary established in Hilden), the Netherlands, and select Asian markets including China (first commercial case at Xiamen Cardiovascular Hospital in March 2017). U.S. commercial approval is being pursued via the RELIVE pivotal trial, a randomized evaluation of approximately 135 subjects that enrolled its first patient at Saint Luke's Mid America Heart Institute in November 2025. Pricing is not publicly disclosed and is negotiated through hospital procurement and reimbursement channels; Germany's consecutive NUB Status 1/1a designations (renewed for 91 hospitals in 2026) enable participating hospitals to negotiate full reimbursement coverage.

Headquartered in Mansfield, Massachusetts (relocated from San Ramon, California), BioVentrix operates with a small team of 1–10 employees and has treated more than 230 patients globally with LIVE Therapy as of mid-2020, reporting zero deaths and zero complications in its most recent 35 consecutive European cases alongside 30–40% left ventricular volume reduction and 17–34% ejection fraction improvement. The company has raised over $230 million in cumulative disclosed funding since 2009, headlined by a $48.5 million Series A in April 2023 led by Andera Partners. In January 2022 BioVentrix acquired MateraCor, Inc. to add an injectable hydrogel heart failure therapy to its portfolio, and in February 2026 it filed for an IPO on Nasdaq (ticker BVXX) seeking up to $17 million with The Benchmark Company as sole bookrunner.

Name

BioVentrix

Legal name

BioVentrix, Inc.

Website

https://bioventrix.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

BioVentrix is a clinical-stage medical device company developing the Revivent System, a minimally invasive cardiac remodeling platform using titanium micro-anchors to exclude scar tissue in ischemic heart failure patients, serving hospitals and Heart Teams in Europe and the US.

Ownership category

akta.pro rank

Product category

Cardiac Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industries

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Minimally invasive cardiac devices
• Ventricular restoration therapy
• Heart failure treatment
• Transcatheter cardiac remodeling
• Ischemic cardiomyopathy devices

Headquarters

HQ city

San Ramon

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (Revivent System): BioVentrix generates revenue through the sale of its Revivent System medical devices, consisting of titanium micro-anchor implants with PEEK tethers. The system is currently commercialized in Europe (CE Mark 2016) and in early commercialization stages. The company filed for a $17 million IPO in February 2026 (Nasdaq: BVXX), indicating preparations for public market capital raise and broader commercialization.
2. Clinical Trial / Development Services: Revenue from clinical trial enrollment and study-related activities in the US (RELIVE pivotal trial, previously ALIVE trial).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

BioVentrix develops and sells the Revivent System (Revivent TC System), a minimally invasive cardiac remodeling device that uses titanium micro-anchor implants and PEEK tethers delivered via a hybrid transcatheter approach to reshape the dilated left ventricle and exclude scarred tissue in ischemic heart failure patients. The system is sold to hospitals and heart failure centers in Europe (CE Mark since 2016) and is under US clinical investigation (RELIVE pivotal trial). The LIVE Therapy (Less Invasive Ventricular Enhancement) procedure is performed by a Heart Team combining cardiothoracic surgery and interventional cardiology on a beating heart without cardiopulmonary bypass.

Product overview

BioVentrix is a clinical-stage medical device company developing minimally invasive therapies for heart failure. Its flagship product is the Revivent System (also called Revivent TC System), a catheter-based ventricular enhancement device that uses titanium micro-anchors and PEEK tethers to reshape the dilated left ventricle by excluding scarred tissue, performed via the LIVE (Less Invasive Ventricular Enhancement) procedure. The company acquired MateraCor to add injectable hydrogel therapy to its portfolio. The Revivent System holds CE Mark approval for commercialization in Europe and is undergoing the RELIVE pivotal clinical trial in the United States for FDA premarket approval.

Differentiator

Problem solved

Functional benefit

Brands

• Revivent System: A minimally invasive cardiac remodeling system that uses titanium micro-anchors and PEEK tethers to reshape the dilated left ventricle in patients with ischemic heart failure and reduced ejection fraction (HFrEF). Also referred to as the Revivent TC System or Revivent TransCatheter Ventricular Enhancement System.
• Revivent Therapy
• LIVE (Less Invasive Ventricular Enhancement)

Products and services

• Revivent System (Revivent TC TransCatheter Ventricular Enhancement System) A minimally invasive cardiac remodeling medical device consisting of titanium micro-anchor implants paired with PEEK tethers, delivered via a hybrid transcatheter approach combining cardiothoracic surgery (external anchor through ~4cm chest incision) and interventional cardiology (internal anchor via catheter through the right ventricle). The anchors are drawn together to exclude scarred non-functioning heart wall, reducing left ventricular volume by 30-40% and reshaping the heart to a more normal geometry. Sold to hospitals and heart failure centers in Europe (commercial) and used in US sites under the RELIVE clinical trial (investigational use only).
• MateraCor Injectable Hydrogel Therapy An injectable hydrogel therapeutic technology for treating heart failure, acquired by BioVentrix to expand its portfolio of treatments for left ventricular heart failure and add therapeutic options for heart muscle repair beyond the Revivent System.

Quantifiable outcome

• Left ventricular volume reduction: 30-40% (immediate post-procedure)
• +5 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered strategic_expansion and supporting.

• MateraCor, Inc.strategic_expansionStrategic or Co-development Partner · 27 January 2022BioVentrix acquired MateraCor, a company developing injectable hydrogel for treating heart failure. The acquisition expanded BioVentrix's portfolio of treatments for left ventricular heart failure and added therapeutic options for heart muscle repair beyond the existing Revivent System. Financial terms were not disclosed.
• Philips HealthcaresupportingTechnology or Integration · 17 April 2017Technology integration partner providing HeartNavigator 3.0 cath lab fusion software used in image fusion-guided Revivent TC procedures. The software enables pre-acquired CT scan fusion with fluoroscopy for real-time intra-operative navigation and accurate anchor implant location determination.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Medtronic offers LVADs (HVAD legacy, HeartWare acquisition) and broad cardiac surgery and structural heart portfolios addressing the same refractory HF patient pool as Revivent. Comparable as an incumbent with the Heart Team sales footprint, capital resources, and global reimbursement infrastructure that BioVentrix must eventually match or partner with.
• Boston Scientific: Boston Scientific has a growing structural heart franchise (Watchman, ACURATE neo2) and serves the same cardiology and cardiothoracic surgery customers. Comparable as a broad incumbent with overlapping call points and Heart Team relationships that BioVentrix targets.
• LivaNova: LivaNova has a cardiac surgery portfolio (heart-lung machines, oxygenators, Perceval sutureless valves) and serves the same cardiothoracic surgery customers as BioVentrix's external anchor placement. Comparable as a broad incumbent in cardiac surgery devices with overlapping surgical call points in Heart Team centers.
• Edwards Lifesciences: Edwards Lifesciences is the structural heart leader (TAVR/SAVR via SAPIEN platform) and serves the same heart teams and HF-adjacent patient populations as BioVentrix. Its established relationships with cardiac surgeons and interventional cardiologists make it both a competitor for procedural capacity and a potential strategic acquirer of BioVentrix's differentiated technology.
• Abbott: Abbott markets HeartMate 3 (the leading LVAD) and a structural heart portfolio including MitraClip and Tendyne. Directly competes for treatment of advanced HF patients and has the commercial scale to either displace or acquire emerging ventricular restoration technologies like Revivent.

Emerging players

• BioCardia: BioCardia is developing cardiac cell therapies (e.g., CardiAMP) for ischemic heart failure, addressing an overlapping HFrEF patient population via a different (biologic) modality. Comparable as a clinical-stage HF therapy company competing for the same refractory post-MI LV scar market that BioVentrix's Revivent addresses.
• SynCardia Systems: SynCardia manufactures the temporary Total Artificial Heart (TAH-t) for end-stage biventricular failure patients awaiting transplant. Comparable as a mechanical circulatory support company addressing the same advanced HF continuum that BioVentrix targets, though at a more acute end of the severity spectrum.

Direct peers

• Corvia Medical: Corvia Medical makes the Corvia Atrial Shunt (IASD), an interventional device for heart failure targeting a different HF phenotype (HFpEF). Comparable as a transcatheter structural heart device targeting a refractory HF population underserved by GDMT.
• Ancora Heart: Ancora Heart develops the AccuCinch transcatheter ventricular restoration system, which also reshapes the dilated left ventricle in HFrEF patients via a percutaneous approach. Most directly comparable to BioVentrix in target patient population, mechanism (ventricular reshaping without bypass), and clinical-stage status.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioventrix
• Xx.com/bioventrix

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds18 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioVentrix